Retirement Planning Company of New England’s Inhibikase Therapeutics IKT Stock Holding History

Retirement Planning Company of New England’s Portfolio IKT Stock Details IKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,817	Closed	-$22.9K	–	231
2023 Q1	$22.9K	Sell	5,817 -52	-0.9%	-$217	0.01%	222
2022 Q4	$17.6K	Sell	5,869 -3,976	-40%	-$15.8K	0.01%	224
2022 Q3	$53K	Sell	9,845 -923	-9%	-$4.86K	0.04%	206
2022 Q2	$47K	Sell	10,768 -8,632	-44%	-$50.9K	0.03%	212
2022 Q1	$172K	Sell	19,400 -5,155	-21%	-$41.5K	0.1%	222
2021 Q4	$216K	Buy	+24,555	New	+$271K	0.11%	207

Other funds holding IKT

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

RAM

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

Edgewood Management Greenwich, Connecticut $9.69B AUM 6.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HLA

Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Retirement Planning Company of New England's IKT Position: Q2 2023 in Review

Retirement Planning Company of New England sold out of Inhibikase Therapeutics (IKT) in Q2 2023, closing a stake of 5,817 shares — an estimated $22.9K sold.

Retirement Planning Company of New England first reported a position in IKT in Q4 2021 and held it in 6 quarters. The position peaked at $216K in Q4 2021. 14 funds tracked by Wall St. Rank hold IKT as of Q2 2023.

Retirement Planning Company of New England reported no remaining Inhibikase Therapeutics position as of Q2 2023 after selling out during the quarter.
Retirement Planning Company of New England sold 5,817 Inhibikase Therapeutics shares in Q2 2023, an estimated $22.9K.
Retirement Planning Company of New England first reported a position in Inhibikase Therapeutics in Q4 2021 and held it in 6 quarters.
Retirement Planning Company of New England's Inhibikase Therapeutics position peaked at $216K in Q4 2021.
14 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2023.

Based on Retirement Planning Company of New England's 13F filing for Q2 2023, filed 11 Aug 2023.